King MT - Search Results

1

Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer.

King MT, Viney R, Smith DP, Hossain I, Street D, Savage E, Fowler S, Berry MP, Stockler M, Cozzi P, Stricker P, Ward J, Armstrong BK. King MT, et al. Br J Cancer. 2012 Feb 14;106(4):638-45. doi: 10.1038/bjc.2011.552. Epub 2012 Jan 24. Br J Cancer. 2012. PMID: 22274410 Free PMC article.

2

Phase 1 in the development of a patient-reported measure to quantify perceived inconvenience of radiotherapy: generation of issues.

Sundaresan P, Milross CG, Stockler MR, Costa DS, King MT. Sundaresan P, et al. Among authors: king mt. Qual Life Res. 2016 Sep;25(9):2361-6. doi: 10.1007/s11136-016-1265-y. Epub 2016 Mar 15. Qual Life Res. 2016. PMID: 26980419 Clinical Trial.

3

Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format.

Norman R, Viney R, Aaronson NK, Brazier JE, Cella D, Costa DS, Fayers PM, Kemmler G, Peacock S, Pickard AS, Rowen D, Street DJ, Velikova G, Young TA, King MT. Norman R, et al. Among authors: king mt. Qual Life Res. 2016 Mar;25(3):637-49. doi: 10.1007/s11136-015-1115-3. Epub 2015 Sep 5. Qual Life Res. 2016. PMID: 26342928

4

The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set.

King MT, Norman R, Mercieca-Bebber R, Costa DSJ, McTaggart-Cowan H, Peacock S, Janda M, Müller F, Viney R, Pickard AS, Cella D; Multi-Attribute Utility in Cancer Consortium. King MT, et al. Value Health. 2021 Jun;24(6):862-873. doi: 10.1016/j.jval.2021.01.007. Epub 2021 May 7. Value Health. 2021. PMID: 34119085 Free article.

5

QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30.

King MT, Costa DS, Aaronson NK, Brazier JE, Cella DF, Fayers PM, Grimison P, Janda M, Kemmler G, Norman R, Pickard AS, Rowen D, Velikova G, Young TA, Viney R. King MT, et al. Qual Life Res. 2016 Mar;25(3):625-36. doi: 10.1007/s11136-015-1217-y. Epub 2016 Jan 20. Qual Life Res. 2016. PMID: 26790428 Free article.

6

Erratum to: Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format.

Norman R, Viney R, Aaronson NK, Brazier JE, Cella D, Costa DS, Fayers PM, Kemmler G, Peacock S, Pickard AS, Rowen D, Street DJ, Velikova G, Young TA, King MT. Norman R, et al. Among authors: king mt. Qual Life Res. 2016 Sep;25(9):2401. doi: 10.1007/s11136-016-1289-3. Qual Life Res. 2016. PMID: 27060090 No abstract available.

7

Erratum to: Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format.

Norman R, Viney R, Aaronson NK, Brazier JE, Cella D, Costa DSJ, Fayers PM, Kemmler G, Peacock S, Pickard AS, Rowen D, Street DJ, Velikova G, Young TA, King MT. Norman R, et al. Among authors: king mt. Qual Life Res. 2017 Aug;26(8):2247-2248. doi: 10.1007/s11136-017-1546-0. Qual Life Res. 2017. PMID: 28337638 No abstract available.

8

Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial.

Ediebah DE, Coens C, Zikos E, Quinten C, Ringash J, King MT, Schmucker von Koch J, Gotay C, Greimel E, Flechtner H, Weis J, Reeve BB, Smit EF, Taphoorn MJ, Bottomley A. Ediebah DE, et al. Among authors: king mt. Br J Cancer. 2014 May 13;110(10):2427-33. doi: 10.1038/bjc.2014.208. Epub 2014 Apr 17. Br J Cancer. 2014. PMID: 24743709 Free PMC article.

9

Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).

Roncolato FT, O'Connell RL, Joly F, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Salutari V, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Fehm T, Ledermann J, Roemer-Becuwe C, Stockler MR, King MT, Friedlander ML. Roncolato FT, et al. Among authors: king mt. Gynecol Oncol. 2020 Jan;156(1):45-53. doi: 10.1016/j.ygyno.2019.10.001. Epub 2019 Dec 10. Gynecol Oncol. 2020. PMID: 31836184

10

Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer.

Friedlander M, Butow P, Stockler M, Gainford C, Martyn J, Oza A, Donovan HS, Miller B, King M. Friedlander M, et al. Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S44-8. doi: 10.1111/IGC.0b013e3181bf7fb8. Int J Gynecol Cancer. 2009. PMID: 19955914 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

326 results

Search Page